Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Dynein axonemal heavy chain 10 (DNAH10) is a large, microtubule-associated motor protein that forms part of the inner arm dynein complex in motile cilia and flagella. It functions as an ATPase, converting ATP hydrolysis into mechanical work to generate force toward the minus ends of microtubules within cilia, driving the motility necessary for processes such as sperm flagellar movement and mucociliary clearance in the airways. DNAH10 also plays a role in epithelial cell proliferation, migration, and differentiation, particularly in skin, where its expression correlates with inflammation and barrier function. Mutations or altered activity of DNAH10 are implicated in male infertility due to defective sperm motility, in axonemal/ciliary disorders, and, in animal models, in congenital scoliosis and body axis defects. There are currently no drugs that specifically target DNAH10, nor is it considered a therapeutic target or clinical biomarker.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Dynein axonemal heavy chain 10 (DNAH10).